PRFX stock forecast, quote, news & analysis
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics... Show more
PRF Technologies (PRFX) Stock Analysis: Diversification Across Specialty Pharma and AI-Driven Energy
Key Takeaways
- PRFX has traded in a relatively narrow range over the last 30 days, edging about 0.8% lower from roughly $0.88 to $0.87 between early October and early November 2026.
- The trailing three-month picture is weaker, with shares down approximately 16% amid continued pressure on a low-float, pre-revenue micro-cap.
- Renamed PRF Technologies from PainReform in January 2026, the company now spans specialty pharmaceuticals, ophthalmic drug delivery, and AI-driven solar analytics.
- Legacy lead candidate PRF-110 missed its Phase 3 primary endpoint in late 2024, shifting strategic focus toward the OcuRing-K and DeepSolar platforms.
- A 1-for-5 reverse stock split completed in February 2026 and an auditor going-concern note underline the company's liquidity and capital-structure risks.
- For deeper detail, review PRFX Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading strategies approach active tickers.
Current Market Snapshot
PRF Technologies Ltd. (Nasdaq: PRFX) is a low-priced, pre-revenue micro-cap that has exhibited elevated volatility and relatively thin trading. Over the last 30 days, the stock has largely held within a modest range, moving from about $0.88 in early October to roughly $0.87 by early November 2026 — a decline of less than 1% — despite intermittent intraday swings and occasional volume spikes. This stability stands in contrast to a steeper drawdown over the prior quarter, reflecting both the stock's small float and investors' wait-and-see posture as the company works to fund and advance a diversified platform. Broader sentiment remains shaped by clinical-stage execution risk, limited cash, and the company's pivot beyond its original single-asset focus.
PRF Technologies (PRFX) Business Overview and Competitive Position
PRF Technologies, formerly PainReform Ltd., is a diversified innovation company headquartered in Tel Aviv, Israel. Its pharmaceutical heritage centers on PRF-110, an oil-based, viscous extended-release formulation of the local anesthetic ropivacaine designed for localized post-operative pain relief. After PRF-110 failed to meet its primary endpoint in a Phase 3 bunionectomy trial in late 2024, the company broadened its strategy.
Through a majority stake in LayerBio, PRF is advancing OcuRing-K, a patented, sustained-release, dropless ocular therapy targeting pain and inflammation after cataract surgery. In parallel, its DeepSolar platform applies AI-driven analytics to utility-scale solar assets, with offerings including technical due diligence and AI-based production forecasting developed within NVIDIA's Connect Program. This multi-platform structure reduces reliance on any single program but also leaves the company dependent on external financing, since it has not yet generated significant revenue.
Recent Developments Driving PRFX
The last 30 days have been comparatively quiet on company-specific news, with price action reflecting micro-cap liquidity and sentiment more than a single catalyst. The shares traded within a range of roughly $0.70 to $0.88, punctuated by an unusually volatile session in early November that saw intraday movement across a wide span alongside a sharp volume increase.
Structurally, several recent items continue to frame how investors view PRFX. The corporate name change to PRF Technologies in January 2026 signaled a deliberate shift beyond its original pain-focused pipeline. The February 2026 1-for-5 reverse stock split was intended to support Nasdaq listing compliance, while the auditor's going-concern qualification and a cash balance of about $3.2 million at the end of 2025 highlight the need for additional capital. On the clinical front, a May 2026 announcement that PRF-110 demonstrated sustained 72-hour analgesic activity in a head-to-head preclinical study provided a scientific update, though it did not alter the fact that the asset is no longer the company's primary clinical focus.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, giving traders a way to compare automated approaches rather than relying on a single system. For investors tracking volatile, low-liquidity names where timing and discipline matter, reviewing these AI-driven signals can add another layer of context alongside traditional fundamental and technical research.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors are likely to shape PRFX. The most important near-term question is funding: with an auditor's going-concern warning and limited cash, the company's ability to raise equity or secure strategic partnerships will influence its capacity to advance its programs. On the pharmaceutical side, progress for OcuRing-K toward the next stage of clinical development represents the clearest pipeline catalyst. In energy, DeepSolar's transition from pilots into commercial customer engagements and revenue generation will be closely watched.
Investors should also monitor regulatory and listing-compliance developments, any updated guidance on PRF-110, and broader sector sentiment toward speculative, pre-revenue healthcare and clean-energy names. Because the company has yet to generate meaningful revenue, execution milestones and capital events — rather than traditional earnings fundamentals — are likely to remain the dominant drivers of the stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRFX in -8.51% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PRFX declined for three days, in 358 of 379 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
PRFX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRFX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRFX's RSI Oscillator exited the oversold zone, 44 of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PRFX as a result. In 84 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for PRFX just turned positive on October 28, 2026. Looking at past instances where PRFX's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 154 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.192) is normal, around the industry mean (6.379). P/E Ratio (-0.213) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric